Valuation: Assembly Biosciences, Inc.

Market Cap 574M 502M 463M 429M 815M 54.48B 828M 5.55B 2.16B 26.89B 2.15B 2.11B 92.93B P/E 2026 *
-26.7x
P/E 2027 * -10.1x
Enterprise Value 574M 502M 463M 429M 815M 54.48B 828M 5.55B 2.16B 26.89B 2.15B 2.11B 92.93B EV / Sales 2026 *
12.6x
EV / Sales 2027 * 17.8x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day+0.24%
1 week+5.40%
Current month+5.40%
1 month+26.48%
3 months+1.52%
6 months-7.73%
Current year-14.83%
1 week 26.41
Extreme 26.41
29.94
1 month 21.8
Extreme 21.795
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 01/01/2023
Director of Finance/CFO - 05/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 61 14/12/2017
Director/Board Member 54 20/10/2020
Chairman 70 04/06/2026
Date Insider Type Main position Quantity % Market Cap.
06-17Sell

Chief Financial Officer

-29 0.0002%
06-04Free

Chairman

8,000 0.0514%
06-04Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
+0.24%+5.40%+56.06%+123.50% 573M
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.25%+1.70%+419.39%+621.71% 40.39B
+1.10%+7.77%+28.18%-3.96% 34.38B
-0.16%+8.12%+27.85%+62.55% 34.4B
+1.31%-0.56%+5.12%+33.90% 26.32B
-0.35%+0.09% - - 16.64B
-3.33%+3.15%+71.30%+131.94% 16.14B
+0.32%+0.53%+14.33%+21.47% 13.71B
+3.79%+8.88%+106.63%+106.63% 13.75B
Average +0.19%+4.55%+81.31%+123.02% 24.66B
Weighted average by Cap. +0.05%+5.02%+95.66%+141.15%

Financials

2026 *2027 *
Net sales 45.47M 39.79M 36.67M 33.99M 64.52M 4.32B 65.56M 440M 171M 2.13B 171M 167M 7.36B 32.25M 28.22M 26.01M 24.11M 45.76M 3.06B 46.5M 312M 121M 1.51B 121M 118M 5.22B
Net income -20.46M -17.91M -16.5M -15.3M -29.04M -1.94B -29.51M -198M -76.96M -958M -76.82M -75.16M -3.31B -56.38M -49.34M -45.47M -42.14M -80M -5.35B -81.29M -545M -212M -2.64B -212M -207M -9.13B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
07/07/26 $28.97 +0.24% 177,777
06/07/26 $28.90 +4.16% 179,400
02/07/26 $27.74 +3.93% 199,257
01/07/26 $26.69 -2.87% 204,110
30/06/26 $27.48 +1.93% 249,382
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
28.96USD
Average target price
50.00USD
Spread / Average Target
+72.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock